New Laser Treatment for Prurigo Nodularisdoi:10.1097/DSS.0000000000004100Supplemental Digital Content is Available in the Text.Carmela Pestoni PorvénVanessa Vieira dos SantosJesús del Pozo LosadaAll authors are affiliated with the Salud Galicia, Dermatología y laserterapia, A Coruña, Spain...
Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. ... S Kwatra,S Kammerer - 《Medicom Conference Report Aad》 被引量: 0发表: 2023年 Recent advances in treatment of prurigo nodularis Prurigo nodularis is a ...
Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions.
The U.S. Food and Drug Administration (FDA) and European Medicines Agency accepted filing submissions for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in February 2024. Nemolizumab was also granted U.S. FDA Priority Review for prurigo nodularis. Further submissions to...
Prurigo Nodularis Psoriasis Psoriatic Arthritis Rare Disease Rosacea Skin Cancer Vitiligo Wound CareArticle November 1, 2017 New products for November 2017A round-up of the latest products hitting the dermatology market including treatment for eczema and wounds, plus care for rejuvenating procedures....
our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus and prurigo nodularis. ...
Incyte announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% in adult patients with Hurley stage 1 or 2 hidradenitis suppurativa.
1 study will also be presented for the first time as a late-breaking abstract on Wednesday, October 11, 3:00-3:15 PM CEST (Hall B), providing confirmation of results from the phase III OLYMPIA 2 study that reinforce nemolizumab’s rapid response in patients with prurigo nodularis.2 ...
Moreover, significant up-regulation of Metrnl expression was observed in familial primary localized cutaneous amyloidosis (FPLCA)[42], psoriasis, prurigo nodularis, actinic keratosis and atopic dermatitis and in synovial membranes of human rheumatoid arthritis, thus suggesting a potential role of Metrnl ...
The findings can inform the design of oral medicines and topical creams to treat persistent itch that occurs with various conditions linked to an imbalance in the skin microbiome, such as atopic dermatitis, prurigo nodularis, and psoriasis.